title: Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations.
abstract: Cancer survivors constitute 3.5% of the United States population, but second primary malignancies among this high-risk group now account for 16% of all cancer incidence. Although few data currently exist regarding the molecular mechanisms for second primary cancers and other late outcomes after cancer treatment, the careful measurement and documentation of potentially carcinogenic treatments (chemotherapy and radiotherapy) provide a unique platform for in vivo research on gene-environment interactions in human carcinogenesis. We review research priorities identified during a National Cancer Institute (NCI)-sponsored workshop entitled "Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers." These priorities include 1) development of a national research infrastructure for studies of cancer survivorship; 2) creation of a coordinated system for biospecimen collection; 3) development of new technology, bioinformatics, and biomarkers; 4) design of new epidemiologic methods; and 5) development of evidence-based clinical practice guidelines. Many of the infrastructure resources and design strategies that would facilitate research in this area also provide a foundation for the study of other important nonneoplastic late effects of treatment and psychosocial concerns among cancer survivors. These research areas warrant high priority to promote NCI's goal of eliminating pain and suffering related to cancer.
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA. travisl@mail.nih.gov
authors.forename: Lois B
authors.initials: LB
authors.lastname: Travis
authors.forename: Charles S
authors.initials: CS
authors.lastname: Rabkin
authors.forename: Linda Morris
authors.initials: LM
authors.lastname: Brown
authors.forename: James M
authors.initials: JM
authors.lastname: Allan
authors.forename: Blanche P
authors.initials: BP
authors.lastname: Alter
authors.forename: Christine B
authors.initials: CB
authors.lastname: Ambrosone
authors.forename: Colin B
authors.initials: CB
authors.lastname: Begg
authors.forename: Neil
authors.initials: N
authors.lastname: Caporaso
authors.forename: Stephen
authors.initials: S
authors.lastname: Chanock
authors.forename: Angela
authors.initials: A
authors.lastname: DeMichele
authors.forename: William Douglas
authors.initials: WD
authors.lastname: Figg
authors.forename: Mary K
authors.initials: MK
authors.lastname: Gospodarowicz
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Hall
authors.forename: Michie
authors.initials: M
authors.lastname: Hisada
authors.forename: Peter
authors.initials: P
authors.lastname: Inskip
authors.forename: Ruth
authors.initials: R
authors.lastname: Kleinerman
authors.forename: John B
authors.initials: JB
authors.lastname: Little
authors.forename: David
authors.initials: D
authors.lastname: Malkin
authors.forename: Andrea K
authors.initials: AK
authors.lastname: Ng
authors.forename: Kenneth
authors.initials: K
authors.lastname: Offit
authors.forename: Ching-Hon
authors.initials: CH
authors.lastname: Pui
authors.forename: Leslie L
authors.initials: LL
authors.lastname: Robison
authors.forename: Nathaniel
authors.initials: N
authors.lastname: Rothman
authors.forename: Peter G
authors.initials: PG
authors.lastname: Shields
authors.forename: Louise
authors.initials: L
authors.lastname: Strong
authors.forename: Toshiyasu
authors.initials: T
authors.lastname: Taniguchi
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Tucker
authors.forename: Mark H
authors.initials: MH
authors.lastname: Greene
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D001709:Biotechnology; D002273:Carcinogens; D016022:Case-Control Studies; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003226:Congresses as Topic; D020022:Genetic Predisposition to Disease; D006801:Humans; D008490:Medical Informatics; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000532:radiotherapy; D009381:Neoplasms, Radiation-Induced / Q000139:chemically induced / Q000209:etiology* / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000209:etiology* / Q000235:genetics; D011878:Radiotherapy / Q000009:adverse effects; D012042:Registries; D013048:Specimen Handling; D017741:Survivors / Q000706:statistics & numerical data; D013577:Syndrome; D014481:United States / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents; D002273:Carcinogens